These mice harbored increased numbers of TRM CD4+ cells compared to non-vaccinated mice, suggesting that the viral adjuvant to the cellular vaccination promoted tissue residence of CD4+ cells that could combat tumor recurrence. The gene discussed is CD4; the disease is neoplasm.